Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of Selexipag Sustained Release Formulations in Healthy Males
NCT04266756Phase 1Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jan 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of selexipag in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Maximum Observed Analyte Concentration, Area Under Analyte Concentration From Time Zero to the Last Quantifiable Concentration and 2 more. Started Jan 2020; status: completed.
02
Drugs
selexipag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT04266756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04266756.